Design and use of potent, specific enzyme inhibitors.
D000345:Affinity Labels / Q000138:chemical synthesis; D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000138:chemical synthesis; D001221:Aspartate Carbamoyltransferase / Q000037:antagonists & inhibitors; D001224:Aspartic Acid / Q000031:analogs & derivatives / Q000138:chemical synthesis / Q000494:pharmacology; D002384:Catalysis; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D003201:Computers; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000138:chemical synthesis* / Q000494:pharmacology; D006801:Humans; D010746:Phosphonoacetic Acid / Q000031:analogs & derivatives / Q000138:chemical synthesis / Q000494:pharmacology; D013329:Structure-Activity Relationship; D013816:Thermodynamics
D000345:Affinity Labels; D000964:Antimetabolites, Antineoplastic; D004791:Enzyme Inhibitors; D001224:Aspartic Acid; C013195:sparfosic acid; D001221:Aspartate Carbamoyltransferase; D010746:Phosphonoacetic Acid